Rare diseases
Investigational molecules
Locations
Ostmerheimer Strasse 200, Merheim, 51109 Cologne, Germany
Kliniken der Stadt Koeln gGmbH in Cologne, Germany specialises in clinical trials of conditions such as Non-small cell lung cancer, Breast cancer, Breast cancer female, Non-small cell lung cancer metastatic, and other specialisations. This site conducts important research.
The department is evaluating new oral agents for Idiopathic Pulmonary Fibrosis, with the goal of slowing disease progression and preserving lung capacity.
Research is conducted at Kliniken der Stadt Koeln gGmbH in Cologne, Germany, involving 26 investigators and a total of five active trials.
A focused study on Neurotrophic Keratopathy examines a novel ophthalmic solution designed to promote corneal healing and maintain visual function.
The trial takes place within the Department of Anesthesiology and Critical Care Medicine at Merheim Medical Center, supporting multidisciplinary patient care.
Ongoing investigations target Resectable Stage II‑IIIB Non‑small cell lung cancer and Unresectable Pleural Mesothelioma, testing innovative immunotherapy‑chemo combinations to improve overall survival.
These oncology trials are coordinated at the Merheim campus, leveraging the expertise of 26 investigators across the institution.
A critical‑care trial evaluates high‑dose intravenous vitamin C for severe burn patients, aiming to reduce persistent organ dysfunction and mortality when added to standard therapy.
Conducted at the Merheim Medical Center, the study benefits from the department’s extensive experience in managing complex trauma cases.
While current trials emphasize oncology and respiratory disease, the department retains strong capabilities in treating infection‑related complications in critical care, laying groundwork for future antimicrobial studies.
The facility’s comprehensive infection management program supports patient safety and positions the site for upcoming research initiatives.
Clinical trials currently enrolling participants at this site.
Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer
GermanyPhase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC
GermanyStudy on Tozorakimab for Patients Hospitalized with Severe Viral Lung Infections Needing Oxygen
GermanyStudy comparing rilvegostomig plus chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression
GermanyPhase 2 Study of Imzokitug with drug combination as First‑Line Treatment for Adults with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC)
GermanyStudy of BGB-43395 with letrozole versus CDK4/6 inhibitor drug combination with letrozole in patients with untreated advanced HR‑positive HER2‑negative breast cancer
GermanyA Study of ABBV-706 to Assess Safety and Efficacy Compared with Standard Drug Combination in Adults with Relapsed or Refractory Small Cell Lung Cancer
GermanyPumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%
GermanyVolrustomig in Patients with Unresectable Pleural Mesothelioma and Esophageal Squamous Cell Carcinoma
GermanyCenegermin Eye Drops for Persistent Corneal Epithelial Defect in Patients with Persistent Corneal Epithelial Defect
GermanyStudy of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer
GermanyA study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer
GermanyMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
